Y. Koopman-Keemink

1.3k total citations
28 papers, 684 citations indexed

About

Y. Koopman-Keemink is a scholar working on Hematology, Speech and Hearing and Rheumatology. According to data from OpenAlex, Y. Koopman-Keemink has authored 28 papers receiving a total of 684 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Hematology, 15 papers in Speech and Hearing and 11 papers in Rheumatology. Recurrent topics in Y. Koopman-Keemink's work include Autoimmune and Inflammatory Disorders Research (25 papers), Adolescent and Pediatric Healthcare (15 papers) and Kawasaki Disease and Coronary Complications (6 papers). Y. Koopman-Keemink is often cited by papers focused on Autoimmune and Inflammatory Disorders Research (25 papers), Adolescent and Pediatric Healthcare (15 papers) and Kawasaki Disease and Coronary Complications (6 papers). Y. Koopman-Keemink collaborates with scholars based in Netherlands, United States and Canada. Y. Koopman-Keemink's co-authors include R. ten Cate, Lisette W. A. van Suijlekom‐Smit, Marion A. J. van Rossum, Esther P A H Hoppenreijs, Marinka Twilt, Wineke Armbrust, Nico Wulffraat, François Prince, Simone Gorter and J. Merlijn van den Berg and has published in prestigious journals such as JAMA, Annals of the Rheumatic Diseases and Human Pathology.

In The Last Decade

Y. Koopman-Keemink

24 papers receiving 668 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Y. Koopman-Keemink Netherlands	13	608	363	185	161	137	28	684
Ariane Klein Germany	14	472 0.8×	286 0.8×	91 0.5×	122 0.8×	110 0.8×	46	553
N. N. Kuzmina Russia	6	532 0.9×	249 0.7×	143 0.8×	223 1.4×	115 0.8×	24	686
Diana Milojevic United States	12	381 0.6×	216 0.6×	127 0.7×	119 0.7×	163 1.2×	24	579
Anton Hospach Germany	13	316 0.5×	165 0.5×	111 0.6×	126 0.8×	101 0.7×	36	452
Giulia Bracciolini Italy	7	371 0.6×	248 0.7×	121 0.7×	92 0.6×	71 0.5×	15	419
Frank Weller‐Heinemann Germany	12	325 0.5×	175 0.5×	76 0.4×	111 0.7×	94 0.7×	37	460
Pirjo Tynjälä Finland	9	496 0.8×	214 0.6×	123 0.7×	249 1.5×	86 0.6×	15	639
Ginger Janow United States	8	370 0.6×	162 0.4×	149 0.8×	80 0.5×	140 1.0×	14	493
Maria Ekelund Sweden	9	261 0.4×	128 0.4×	66 0.4×	104 0.6×	80 0.6×	11	406
Elena Palmisani Italy	11	318 0.5×	140 0.4×	77 0.4×	83 0.5×	71 0.5×	37	451

Countries citing papers authored by Y. Koopman-Keemink

Since Specialization

Citations

This map shows the geographic impact of Y. Koopman-Keemink's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Y. Koopman-Keemink with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Y. Koopman-Keemink more than expected).

Fields of papers citing papers by Y. Koopman-Keemink

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Y. Koopman-Keemink. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Y. Koopman-Keemink. The network helps show where Y. Koopman-Keemink may publish in the future.

Co-authorship network of co-authors of Y. Koopman-Keemink

This figure shows the co-authorship network connecting the top 25 collaborators of Y. Koopman-Keemink. A scholar is included among the top collaborators of Y. Koopman-Keemink based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Y. Koopman-Keemink. Y. Koopman-Keemink is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bergstra, Sytske Anne, J. Merlijn van den Berg, Dieneke Schonenberg‐Meinema, et al.. (2024). Increasing the etanercept dose in a treat-to-target approach in juvenile idiopathic arthritis: does it help to reach the target? A post-hoc analysis of the BeSt for Kids randomised clinical trial. Pediatric Rheumatology. 22(1). 53–53. 1 indexed citations

Anink, Janneke, Sytske Anne Bergstra, Dieneke Schonenberg‐Meinema, et al.. (2023). Significant pain decrease in children with non-systemic Juvenile Idiopathic Arthritis treated to target: results over 24 months of follow up. Pediatric Rheumatology. 21(1). 90–90. 1 indexed citations

Müller, P, Dominique Schreurs, Charlotte M. Nusman, et al.. (2019). No radiographic wrist damage after treatment to target in recent-onset juvenile idiopathic arthritis. Pediatric Rheumatology. 17(1). 62–62. 3 indexed citations

Müller, Petra, D. M. C. Brinkman, Dieneke Schonenberg‐Meinema, et al.. (2018). Treat to target (drug-free) inactive disease in DMARD-naive juvenile idiopathic arthritis: 24-month clinical outcomes of a three-armed randomised trial. Annals of the Rheumatic Diseases. 78(1). 51–59. 51 indexed citations

Müller, P, Dieneke Schonenberg‐Meinema, Y. Koopman-Keemink, et al.. (2017). Three Treatment Strategies in Recent Onset DMARD Naive Juvenile Idiopathic Arthritis : First Results of Clinical Outcome after 24 Months. Data Archiving and Networked Services (DANS). 69.

Müller, P, D. M. C. Brinkman, D. Schonenberg, et al.. (2017). A comparison of three treatment strategies in recent onset non-systemic Juvenile Idiopathic Arthritis: initial 3-months results of the BeSt for Kids-study. Pediatric Rheumatology. 15(1). 11–11. 31 indexed citations

Anink, Janneke, Femke H. M. Prince, M.H. Otten, et al.. (2015). Long-term quality of life and functional outcome of patients with juvenile idiopathic arthritis in the biologic era: a longitudinal follow-up study in the Dutch Arthritis and Biologicals in Children Register. Lara D. Veeken. 54(11). 1964–1969. 29 indexed citations

Bandsma, Robert, Harry van Goor, Michael Yourshaw, et al.. (2015). Loss of ADAM17 is associated with severe multiorgan dysfunction. Human Pathology. 46(6). 923–928. 31 indexed citations

Müller, Petra, D. Schonenberg, Y. Koopman-Keemink, et al.. (2015). OP0068 Three Treatment Strategies in Recent Onset DMARD Naïve Juvenile Idiopathic Arthritis: Initial Results of the Best for Kids-Study. Annals of the Rheumatic Diseases. 74. 94–94.

10.

Otten, M.H., Janneke Anink, Femke H. M. Prince, et al.. (2014). Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register. Annals of the Rheumatic Diseases. 74(7). 1379–1386. 36 indexed citations

11.

Otten, M.H., Femke H. M. Prince, Janneke Anink, et al.. (2012). Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC Register. Annals of the Rheumatic Diseases. 72(5). 721–727. 40 indexed citations

12.

Anink, Janneke, M.H. Otten, Femke H. M. Prince, et al.. (2012). Tumour necrosis factor-blocking agents in persistent oligoarticular juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children Register. Lara D. Veeken. 52(4). 712–717. 11 indexed citations

13.

Prince, François, Marinka Twilt, Marion A. J. van Rossum, et al.. (2011). An analysis of the costs and treatment success of etanercept in Juvenile Idiopathic Arthritis. Clinical and Experimental Rheumatology. 29(2). 443–443. 1 indexed citations

14.

Otten, M.H., Femke H. M. Prince, Marinka Twilt, et al.. (2011). Tumor Necrosis Factor-blocking Agents for Children with Enthesitis-related Arthritis — Data from the Dutch Arthritis and Biologicals in Children Register, 1999–2010. The Journal of Rheumatology. 38(10). 2258–2263. 54 indexed citations

15.

Prince, François, Marinka Twilt, Marion A. J. van Rossum, et al.. (2011). An analysis of the costs and treatment success of etanercept in juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children register. Lara D. Veeken. 50(6). 1131–1136. 20 indexed citations

16.

Otten, M.H., François Prince, R. ten Cate, et al.. (2010). Tumour necrosis factor (TNF)-blocking agents in juvenile psoriatic arthritis: are they effective?. Annals of the Rheumatic Diseases. 70(2). 337–340. 16 indexed citations

17.

Otten, M.H., Femke H. M. Prince, Marinka Twilt, et al.. (2010). Delayed Clinical Response in Patients with Juvenile Idiopathic Arthritis Treated with Etanercept. The Journal of Rheumatology. 37(3). 665–667. 6 indexed citations

18.

Prince, François, Lianne M. Geerdink, G. J. J. M. Borsboom, et al.. (2009). Major improvements in health-related quality of life during the use of etanercept in patients with previously refractory juvenile idiopathic arthritis. Annals of the Rheumatic Diseases. 69(1). 138–142. 44 indexed citations

19.

Prince, François, Marinka Twilt, R. ten Cate, et al.. (2008). Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Annals of the Rheumatic Diseases. 68(5). 635–641. 158 indexed citations

20.

Prince, François, Sylvia Kamphuis, Wineke Armbrust, et al.. (2008). Development of a web-based register for the Dutch national study on biologicals in JIA: www.ABC-register.nl. Lara D. Veeken. 47(9). 1413–1416. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact